Research Paper Volume 12, Issue 1 pp 122—137

PRDX5 as a novel binding partner in Nrf2-mediated NSCLC progression under oxidative stress

Figure 8. Effect of Nrf2 and PRDX5 shRNA on tumor growth in vivo. (A) Representative xenografts in each group. (B) The weights of xenograft tumors in mice after treatment with each shRNA. (*,#P < 0.05, **P < 0.01). (C) Antitumor therapeutic efficacy in tumor bearing mice (*P < 0.05, **P < 0.01). (D and E) The protein expressions of Nrf2, PRDX5 and NQO1 in xenograft tumors in each group. (*,#,&P < 0.05, compared with the control group, respectively).